N@N

NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference

_{//health-fitness.news-articles.net/content/2010/ .. sent-at-ubs-global-life-sciences-conference.html}
^{Published in Health and Fitness on Tuesday, September 14th 2010 at 13:20 GMT by Market Wire}  

BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will present at the UBS Global Life Sciences Conference in New York on Monday, September 20, 2010 at 3:00 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa™ calendar of events page on the NPS website at [ http://www.npsp.com/events ].

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX^® in a Phase 3 registration study known as STEPS for parenteral nutrition dependent short bowel syndrome and is in preclinical development for pediatric indications and chemotherapy-induced gastrointestinal mucositis. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at [ http://www.npsp.com ].